Pharmacotherapies for Spinal Cord Injury: Current Status

Abstract

CLC Number:

R965.1

XIAO Han-ping1, WANG Shuo-yu2, LI Hua-nan2, ZHANG Shui-yin1, GU Bing1. Pharmacotherapies for Spinal Cord Injury: Current Status[J]. Acta Neuropharmacologica, 2012, 2(2): 32-36.

[1] J Marc Simard, Ming-kui Chen, Kirill V Tarasov, et al. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke[J]. Nat Med, 2006, 12(4): 433-440.

[2] Toshihiro Takami, Martin Oudega, John R Bethea, et al. Methylprednisolone and interleukin-10 reduce gray matter damage in the contused Fischer rat thoracic spinal cord but do not improve functional outcome [J]. J Neurotrauma, 2002, 19(5): 653- 666.

[3] Daniel P Lammertse. Update on pharmaceutical trials in acute spinal cord injury[J]. J Spinal Cord Med, 2004, 27(4): 319-325

[4] Michael B Bracken, Mary J Shepard, William F Collin, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study[J]. N Engl J Med, 1990, 322(20): 1405-1411.

[5] Justin P Kubeck, Andrew Merola, Sameer Mathur, et al. End organ effects of high-dose human equivalent methylprednisolone in a spinal cord injury rat model[J]. Spine (Phila Pa 1976), 2006, 31(3): 257-261.

[6] Michael B Bracken, Mary Jo Shepard, Theodore R Holford, et al. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial[J]. J Neurosurg, 1998, 89(5): 699-706.

[7] Elaine E Tseng, Malcolom V Brock, Mary S Lange, et al. Monosialoganglioside GM1 inhibits neurotoxicity after hypothermic circulatory arrest[J]. Surgery, 1998, 124(2): 298-306.

[8] 王易虎, 易南, 张灿久. 康复训练加神经节苷脂对脊髓损伤恢复期的治疗作用[J]. 中国临床康复, 2003, 7(26): 3604-3605.

[9] Seidl E C. Promising pharmacological agents in the management of acute spinal cord injury[J]. Pharm Pract Manag Q, 2000, 20(1): 21-27.

[10] Darryl C Baptiste, Michael G Fehlings. Pharmacological approaches to repair the injured spinal cord[J]. J Neurotrauma, 2006, 23(3): 318-334.

[11] Judith B Walker, Michelle Harris. GM-1 ganglioside administration combined with physical therapy restores ambulation in humans with chronic spinal cord injury[J]. Neurosci Lett, 1993, 161(2): 174-178.

[12] Fred H Geisler, William P Coleman, Giacinto Grieco, et al. The Sygen multicenter acute spinal cord injury study[J]. Spine (Phila Pa 1976), 2001, 26(24): S87-S98.

[13] Michael G Fehlings, Darryl C Baptise. Current status of clinical trials for acute spinal cord injury[J]. J Injure, 2005, 36(l2): B113-B122.

[14] Stewart J E, Barbeau H, Gauthier S. Modulation of locomotor patterns and spasticity with clonidine in spinal cord injured patients[J]. Can J Neurol Sci, 1991, 18(3): 321-332.

[15] Rémy-Néris O, Barbeau H, Daniel O, et al. Effects of intrathecal clonidine injection on spinal reflexes and human locomotion in incomplete paraplegic subjects[J]. Exp Brain Res, 1999, 129(3): 433-440.

[16] Wainberg M, Barbeau H, Gauthier S. The effects of cyproheptadine on locomotion and on spasticity in patients with spinal cord injuries[J]. J Neurol Neurosurg Psychiatry, 1990, 53(9): 754-763.

[17] Fung J, Stewart J E, Barbeau H. The combined effects of clonidine and cyproheptadine with interactive training on the modulation of locomotion in spinal cord injured subjects[J]. J Neurol Sci, 1990, 100(1-2): 85-93.

[18] Kathleen E Norman, Andrew Pépin, Hugues Barbeau. Effects of drugs on walking after spinal cord injury[J]. Spinal Cord, 1998, 36(10): 699-715.

[19] Ozerk Okutan, Ihsan Solaroglu, Etem Beskonakli, et al. Recombinant human erythropoietin decreases myeloperoxidase and caspase-3 activity and improves early functional results after spinal cord injury in rats[J]. J Clin Neurosci, 2007, 14(4): 364-368.

[20] Anna-Leena Sirén, Theresa Fasshauer, Claudia Bartels, et al. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system[J]. Neurotherapeutics, 2009, 6(1): 108-127.

[21] Hyung Chun Park, Yoo Shik Shim, Yoon Ha, et al. Treatment of complete spinal cord injury patients by autologous bone marrow cell transplantation and administration of granu locyte-macrophage colony stimulating factor[J]. Tissue Eng, 2005, 11(5-6): 913-922.

[22] L Jackson II Roberts, John A Oates, MacRae F Linton, et al. The relationship between dose of vitamin E and suppression of oxidative stress in humans[J]. Free Radic Biol Med, 2007, 43(10): 1388-1393.

[23] 龚耀成, 梁裕. 甲钴胺治疗下腰椎疾患: Ⅲ期临床试验[J]. 中国新药与临床杂志,2000, 19(2): 124-126.

[24] Segal J L, Brunnemann S R. 4-Aminopyridine alters gait characteristics and enhances locomotion in spinal cord injured humans[J]. J Spinal Cord Med, 1998, 21(3): 200-204.

[25] Jack L Segal, Mayank S Pathak, Jesus P Hernandez, et al. Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial[J]. Pharmacotherapy, 1999, 19(6): 713-723.

[26] van der Bruggen M A, Huisman H B, Beckerman H, et al. Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury[J]. J Neurol, 2001, 248(8): 665-671.

[27] DeForge D, Nymark J, Lemaire E, et al. Effect of 4-aminopyridine on gait in ambulatory spinal cord injuries: a double-blind, placebo-controlled, crossover trial [J]. Spinal Cord, 2004, 42(12): 674-685.

[28] Israel Grijalva, Gabriel Guízar-Sahagún, Gilberto Castañeda-Hernández, et al. Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial[J]. Pharmacotherapy, 2003, 23(7): 823-834.

[29] Israel Grijalva, Gabriel Guízar-Sahagún, Delia Rodríguez-Pacheco, et al. Gastric emptying effect by 4-aminopyridine in patients with chronic spinal cord injury[J]. Arch Med Res, 2007, 38(4): 392-397.

[30] David J McAdoo, Michael G Hughes, Linghui Nie, et al. The effect of glutamate receptor blockers on glutamate release following spinal cord injury. Lack of evidence for an ongoing feedback cascade of damage --> glutamate release --> damage --> glutamate release --> etc[J]. Brain Res, 2005, 1038(1): 92-99.

[31] Darryl C Baptiste, Michael G Fehlings. Update on the treatment of spinal cord injury[J]. Prog Brain Res, 2007, 161: 217-233.

[32] Coderre T J, Kumar N, Lefebvre C D, et al. A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain[J]. J Neurochem, 2007, 100(5): 1289-1299.

[33] Michael G Fehlings, Jefferson R Wilson, Ralph F Frankowski, et al. Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial[J]. Neurosurg Spine, 2012, 17(1 Suppl): 151-156.

[34] Nanna B Finnerup, Fin Biering-Sørensen, Inger L Johannesen, et al. Intravenous lidocaine relieves spinal cord injury pain: a randomized controlled trial[J]. Anesthesiology, 2005, 102(5): 1023-1030.

[35] Alexander G Rabchevsky, Samir P Patel, Joe E Springer. Pharmacological interventions for spinal cord injury: where do we stand? How might we step forward? [J]. Pharmacol Ther, 2011, 132(1): 15-29.

[36] Alan I Faden, Thomas P Jacobs, Michael T Smith. Evaluation of the calcium channel antagonist nimodipine in experimental spinal cord ischemia[J]. J Neurosurg, 1984; 60(4): 796-799.

[37] Diana S L Chow, Yang Teng, Elizabeth G Toups, et al. Pharmacology of riluzole in acute spinal cord injury[J]. J Neurosurg Spine, 2012, 17(1 Suppl): 129-140.

[38] 李明, 叶晓健, 余科炜, 等. 纳洛酮治疗急性脊髓损伤的临床观察[J]. 中国矫形外科杂志, 1997, 4(4): 280-281.

[39] Michael B Bracken, Mary J Shepard, William F Jr Collins, et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study[J]. J Neurosurg, 1992, 76(1): 23-31.

[40] Natasha Olby. Current concepts in the management of acute spinal cord injury[J]. J Vet Intern Med, 1999, 13(5): 399-407.

[41] Drug C Baptiste, Allyson Tighe, Michael G Fehlings. Spinal cord injury and neural repair: focus on neuroregenerative approaches for spinal cord injury[J]. Expert Opin Investig Drugs, 2009, 18(5): 663-673.

[42] Kopp M A, Liebscher T, Niedeggen A, et al. Small-molecule-induced Rho-inhibition: NSAIDs after spinal cord injury[J]. Cell Tissue Res, 2012, 349(1): 119-132.

[43] Michael G Fehlings, Nicholas Theodore, James Harrop, et al. A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury[J]. J Neurotrauma, 2011, 28(5): 787-796.

[44] Brad A Bryan, Emily Dennstedt, Dianne C Mitchell, et al. RhoA/ROCKsignaling is essential for multiple aspects of VEGF-mediatedangiogenesis[J]. FASEB J, 2010, 24(9): 3186-3195.

Pharmacotherapies for Spinal Cord Injury: Current Status

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 8

Recommended Articles

Metrics

[1]	YANG Xu-hua, DU Shuang, SHEN Li-xia, HAO Jun-rong. Research Progress in Drug Treatment of Alzheimer’s Disease [J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(3): 47-53.
[2]	XIA Xiao-wen，SONG Chun-hong，QIAO Ming-qi, et al. Research Progress on the Mechanism of PMDD [J]. Acta Neuropharmacologica, 2019, 9(6): 36-40.
[3]	LONG Sen，CHEN Jia-ye，HAN Feng. Mechanisms of Autism Spectrum Disorder and Pharmacological Approach [J]. Acta Neuropharmacologica, 2016, 6(6): 55-64.
[4]	ZHANG Si, GU Bing, WANG Shuo-yu, LI Hua-nan, ZHANG Guo-fu, ZHANG Shui-yin. Effects of Methotrexate on Acute Phrase of Spinal Cord Contusion-Induced Lipid Peroxidation in Rats [J]. Acta Neuropharmacologica, 2014, 4(1): 11-16.
[5]	ZHANG Si, WANG Shuo-yu, GU Bing, LI Hua-nan, ZHANG Guo-fu, ZHANG Shui-yin. Effects of Low-dose Methotrexate on Spinal Cord Contusion-Induced Neural Cell Apoptisis in Rats [J]. Acta Neuropharmacologica, 2013, 3(6): 1-8.
[6]	ZHANG Si, GU Bing, LI Hua-nan, ZHANG Guo-fu, ZHANG Shui-yin, MIN You-jiang . Induced Pluripotent Stem Cells and Their Transplantation for Spinal Cord Injury: Current Status [J]. Acta Neuropharmacologica, 2013, 3(3): 57-64.
[7]	ZHANG Si, WANG Shuo-yu, LI Hua-nan, ZHANG Guo-fu, GU Bing. Oxidative Stress and Antioxidant Therapy after Acute Spinal Cord Injury [J]. Acta Neuropharmacologica, 2012, 2(3): 52-64.
[8]	GU Bing, WANG Shuo-yu, LI Hua-nan, WANG Jun, ZHANG Shui-yin. A Comparative Morphological Study on Early Stage Treatment of Rat Spinal Cord Contusion with Recombinant Human Erythropoietin and Methylprednisolone [J]. ACTA NEUROPHARMACOLOGICA, 2011, 1(6): 7-16.